We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · June 13, 2013

Bevacizumab Breaks Ground in Cervical Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Incorporation of Bevacizumab in the Treatment of Recurrent and Metastatic Cervical Cancer: A Phase III Randomized Trial of the Gynecologic Oncology Group
J. Clin. Oncol 2013 Jun 02;[EPub Ahead of Print], KS Tewari, M Sill, HJ Long, LM Ramondetta, LM Landrum, A Oaknin, TJ Reid, MM Leitao, HE Michael, BJ Monk

Further Reading